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Autoantibody Detection for Diagnosis in
Direct Immunofluorescence-Negative
Mucous Membrane Pemphigoid
Ocular and Other Sites Compared
John Dart, DM, FRCOphth,1 Jane Setterfield, MD, FRCP,2 Richard W. Groves, MBChB,3,4 John B. Mee, PhD,3
Gilles F.H. Diercks, MD, PhD,5 Hendri H. Pas, PhD,6 Darwin Minassian, MSc,7 for the Mucous Membrane
Pemphigoid Study Group 2009e2014*
Purpose: To assess whether a panel of serum pemphigoid autoantibody tests could be used to confirm an
immunopathologic diagnosis of mucous membrane pemphigoid (MMP) in direct immunofluorescent negative
(DIFe) MMP patients.
Design: Prospective cross-sectional study.
Participants: Seventy-six patients with multisite MMP with 45 matched control participants.
Methods: Enzyme-linked immunosorbent assays (ELISAs) for BP180 and BP230 (MBL International,
Woburn, MA), immunoglobulin A (IgA) A and immunoglobulin G indirect immunofluorescence (IIF) on human salt-
split skin and the keratinocyte footprint assay for antielaminin 332 antibodies.
Main Outcome Measures: Sensitivity and specificity of autoantibody detection and significant differences
for individual tests and test combinations for MMP involving different sites.
Results: All DIFe patients (24/73 [31.8%]) had either ocular-only disease or ocular involvement in multisite
disease. Serum pemphigoid autoantibodies were detected in 29 of 76 MMP patients (38.2%) compared with 3 of
45 control participants (6.7%). Autoantibody reactivity detected by any 1 or more of the tests was present in 6 of
24 DIFe patients (25%) compared with 22 of 49 DIF positive (DIFþ) patients (44.9%). Ocular-only MMP serum
reactivity was not significantly different for any test or test combination compared with control participants,
whereas DIFe multisite ocular MMP differed for 1 ELISA and 3 of 7 test combinations. By contrast, for DIFþ
nonocular MMP patients, all the individual tests, apart from IgA IIF, and all test combinations were significantly
different compared with those for control participants. For the entire MMP cohort, the sensitivity of all individual
tests was low, having a maximum of 21.05% for BP180 reactivity but increasing to 38.16% for an optimal test
combination. Disease activity was associated strongly with positive serologic findings.
Conclusions: Pemphigoid serum autoantibody tests did not provide immunopathologic evidence of MMP in
ocular-only MMP patients but showed limited value in DIFe multisite ocular MMP patients. The requirement for
immunopathologic confirmation of MMP by autoantibody detection is inappropriate for DIFe ocular-only MMP
patients, resulting in missed diagnoses, delayed therapy, and poor outcomes. Alternative diagnostic criteria for
ocular-only MMP are required to exclude the other causes of scarring conjunctivitis until more sensitive and
specific immunopathologic tests become available. Ophthalmology 2020;-:1e11 ª 2020 by the American
Academy of Ophthalmology
Supplemental material available at www.aaojournal.org.Mucous membrane pemphigoid (MMP) is an autoimmune
subepidermal blistering disease. Autoantibodies are usually
present and directed against different components of the
epithelial basement membrane (BM) of the mucosal orifices,
with or without skin involvement. All pemphigoid disorders
with predominant involvement of mucous membranes are
termed MMP.1 Mucous membrane pemphigoid patients
with lesions limited to ocular and oral sites have been
termed ocular-only MMP patients, synonymous with pureª 2020 by the American Academy of Ophthalmology
Published by Elsevier Inc.ocular MMP2 or oral-only MMP.3 The conjunctiva is
involved in two thirds of MMP patients.1
Mucous membrane pemphigoid diagnosis currently re-
quires both clinical criteria and biopsy results showing
immunoglobulin G (IgG), immunoglobulin A (IgA), or com-
plement at the epithelial BM zone, indicating the presence of
autoantibodies, using either direct immunofluorescence (DIF)
or immunohistochemistry and immunoelectron microscopy.
Direct immunofluorescence positive (DIFþ) findings from1https://doi.org/10.1016/j.ophtha.2020.07.052
ISSN 0161-6420/20
Ophthalmology Volume -, Number -, Month 2020any 1 site are accepted as diagnostic immunopathologic evi-
dence for disease at any other site thatmeets the clinical criteria
for MMP.1 Biopsy samples for DIF are obtained from
perilesional tissue of affected sites,1 including, where
possible, uninflamed conjunctiva, but biopsy samples from
clinically unaffected sites may also show positive results.4
However, biopsy samples cannot always be obtained for DIF
(consent may be declined or conjunctiva may be inaccessible
in advanced ocular disease) and, furthermore, are less
sensitive in ocular-only MMP than for MMP at other
sites,5e7 with positive results found in only approximately
50% of patients, despite the use of multiple biopsy samples.3,8
When negative DIF (DIFe) results are found or results are
unavailable, the detection of circulating epithelial basement
membrane autoantibodies in serum can be used to confirm
the diagnosis.1 In MMP, 6 target antigens have been
recognized as pemphigoid autoantibodies, including BP180
(also termed collagen type XVII), BP230, and laminin 332,
for which tests are widely available.9e14 Pemphigoid autoan-
tibodies have been detectable in variable proportions of MMP
patients, from as low as 10% for IIF salt-split skin (SSS), to 0%
for immunoblotting or immunoprecipitation for BP180 and
BP230 in a subset of 10 ocular-onlyMMPpatients,15 to as high
as 84%16 for MMP patients having mixed site involvement.
Our primary hypothesis was that a panel of serum pem-
phigoid autoantibody tests and their combinations might be
used to confirm an immunopathologic diagnosis of MMP in
DIFe patients with ocular involvement. The hypothesis was
tested by evaluating the sensitivity and specificity of tests
and their combinations for patients with that of age-,
gender-, and race-matched control participants.Methods
The study was approved by the UK Research Ethics Service
(reference no., 09/H0721/54) and adhered to the tenets of the
Declaration of Helsinki. This was a prospective cross-sectional
study of patients diagnosed with MMP and an age-, gender-, and
race-matched control population, all of whom donated blood for
these serologic studies. Patients and control participants provided
informed consent and were recruited between December 21, 2009,
and August 5, 2011.
Patients
Mucous membrane pemphigoid patients were recruited from
among both existing patients and new referrals at 2 London clinics,
the Corneal and External Disease Clinic of Moorfields Eye Hos-
pital NHS Foundation Trust and the Oral Medicine and Derma-
tology Clinics of Guys and St. Thomas’s NHS Foundation Trust.
The results of previous DIF tests were recorded, and if these had
not been carried out, a biopsy sample was obtained and processed
for DIF using standard techniques.17 The diagnosis of MMP for
patients with ocular involvement, without positive DIF results,
was based on the clinical and pathologic criteria that we
proposed previously for this subset of patients.3,8,18 Data were
collected using a case report form designed for this study.3 A
history was obtained from all MMP patients, focusing on
previous involvement of sites of MMP and general health, and
all MMP patients underwent an examination for signs of MMP
at all potential anatomic sites, apart from the esophagus, by
ophthalmologists, a dermatologist, an oral medicine specialist,2
and otolaryngologists. Some patients declined the additional
examinations for screening of extraocular sites (13 oral, 14 skin,
37 nasopharyngeal, 15 genital, and 16 perianal). The history of
disease at all sites was used to classify patients by site of
involvement, both those whose disease was in remission with no
residual clinical signs (common in oral MMP) and when the
additional examinations had been declined. The sites assessed for
involvement by MMP and screening criteria for involvement at
these sites have been described and tabulated.3
Control Participants
The number of control participants in this study (n¼ 45) was chosen
a priori to give an 80%power to detect a difference in the proportions
of BP180-NC16a autoantibodies. This was calculated using Wie-
land’s data on age, 14 of 337 (4.15%) gender-stratified control par-
ticipants having detectable levels,19 and our pilot data fromourMMP
patients showing 8 of 32 patients (25%) had detectable levels. Age-,
gender-, and race-matched control participants were recruited from
among healthy staff and patients who were undergoing surgery for
ocular conditions, without associated systemic disease.
Serologic Tests
The serology test results analyzed in this study were duplicated in a
service laboratory in 2014 and 2015 and in the laboratory of the
Centre for Blistering Diseases, The University of Groningen, in
2018 and 2019; discrepancies between the 2 sites were retested at
the St. John’s Institute of Dermatology Laboratory in 2019. This
was carried out to resolve the issue of unreliable data provided by
the service laboratory that became apparent in 2018. The sera were
stored at the UCL Institute of Ophthalmology, London, at e80 C
until March 2018 and at e20 C thereafter. Laboratory staff were
masked to the clinical findings.
Table 1 describes the 5 tests carried out on the sera for all 76
patients and 45 control participants. The 51 discrepancies
between the Groningen and service laboratory results were
retested by St. John’s. For the 45 patients for which the
Groningen results were confirmed by St. John’s, the Groningen
results were used for the analysis. The service laboratory
findings were used for the remaining 6 tests after the
discrepancies with Groningen were confirmed by 2 repeat tests at
St. John’s. Laminin 332 reactivity was reported only for the
Groningen keratinocyte footprint assay20 results. Indirect
immunofluorescence was carried out using human SSS, although
protocols varied because no standards exists for this test.21 The
MBL International (Woburn, MA) enzyme linked
immubosorbent assays (ELISAs) were carried out according to
the manufacturer’s protocol, but procedures differed between
these laboratories with regard to the reporting of the results; at
Groningen, sera with ELISA results of 6 U/ml or more were
retested up to twice more, and the results scored as positive if at
least 2 tests met the manufacturer’s recommended cutoff of 9 U/
ml or more and were scored as negative if any 2 tests showed
lower concentrations than this. At the service laboratory,
participants with results of 9 U/ml or more were recorded as
positive unless a test showed only weakly positive results when
it was repeated and were reported as positive when the repetition
was positive, or the results were recorded as negative if the
repeat test showed negative results. At St. John’s, results were
reported as positive when the results met the manufacturer’s
recommended cutoff of 9 U/ml or more.
Statistical Analysis
The sensitivity and specificity were computed for those autoanti-
body tests showing a significantly higher frequency of positive
Table 1. Descriptions of the 5 Tests Used to Detect Serum Pemphigoid Autoantibodies in Mucous Membrane Pemphigoid Patients, the Proportions of Positive Results Compared
with Those of Control Participants, Sensitivity, Specificity, and Youden’s Index
Test No.*
Antigens and
Substrates Test Methodologyy z











cutoff < 9 U/ml
16 (21.05) 2 (4.44) 0.016 21.05 95.56 16.61
2 ELISA BP230
MBL
10 (13.16) 1 (2.22) 0.052 13.16 97.78 10.94
3 IgA IIF SSS Indirect
immunofluorescence
on human 1-molar SSS
5 (6.58) 0 (0.00) 0.156 6.58 100 6.58







3 (3.95) 0 (0.00) 0.233 3.95 100 3.95
Combined reactions
1 þ 2 19 (25.00) 3 (6.67) 0.014 25.00 93.33 18.33
3 þ 4 13 (17.11) 0 (0.00) 0.002 17.11 100 17.11
1 þ 3 þ 4 25 (32.89) 2 (4.44) < 0.001 32.89 95.56 28.45
1 þ 2 þ 3 þ 4 26 (34.21) 3 (6.67) < 0.001 34.21 93.33 27.54
1 þ 3 þ 4 þ 5 28 (36.84) 2 (4.44) < 0.001 36.84 95.56 32.40
2 þ 3 þ 4 þ 5 23 (30.26) 1 (2.22) < 0.001 30.26 97.78 28.04
1 þ 2 þ 3 þ 4 þ 5 29 (38.16) 3 (6.67) < 0.001 38.16 93.33 31.49
ELISA ¼ enzyme-linked immunosorbent assay; IgA ¼ immunoglobulin A; IgG ¼ immunoglobulin G; IIF ¼ indirect immunofluorescence; KFA ¼ Keratinocyte footprint assay; SSS ¼ salt-split skin.
Statistically significant P values were defined as <0.05 and have been identified in boldface.
*Test numbering is used in Figures 1e3.
yAll tests were from 76 patients and 45 control participants, apart from the BP230 ELISA, which were performed on only 60 of 76 MMP patients at the service laboratory.

















Table 2. Clinical Characteristics of Mucous Membrane Pemphigoid Patients and Control Participants, Direct Immunofluorescence Results, and Serum Pemphigoid Autoantibody
Test Results for All Participants and Participants with Both Limited-Site and Multiple-Site Involvement
Demographics
All Mucous Membrane Pemphigoid
Patients











No. (%) 76 18 15 14 20 16 8 14 45




59.9 (14.6) 63.2 (18.0) 55.4 (10.5) 61.1 (10.0) 63.7 (9.5) 57.4 (17.7) 66.25 (7.8) 57.4 (15.2) 61.4 (13.1)
Range 18e83 24e83 38e75 47e81 47e81 18e78 56e76 23e74 18e86
White race, no. (%)y 64 (91.4) 16 (88.9) 13 (100) 11 (91.7) 15 (83.3) 14 (93.3) 5 (71.4) 11 (84.6) 42 (93)
Race not declared, no.z 6 0 2 2 3 1 1 1 0
Systemic immunotherapy,
no. (%)





Positive 49 (67.1) 6 (35.3) 12 (80) 13 (100) 19 (100) 11 (68.7) 4 (57.1) 9 (64.3)
Negative (all ocular)x 24 (32.9) 11 (64.7) 3 (20) 0 (0.0) 0 (0.0) 5 (31.3) 3 (42.9) 5 (35.7)
Unknownz 3 1 0 1 1 0 1 0
Serum autoantibody
results, no. (%)
Any positive 29 (38.2) 3 (16.7) 5 (33.3) 9 (64.3) 13 (65.0) 7 (43.8) 6 (75.0) 5 (35.7) 3 (6.7)
Positive in DIFþ 22/49 (44.9) 1/6 (16.7) 5/12 (41.7) 8/13 (61.5) 12/19 (63.2) 5/11 (45.5) 3/4 (75.0) 3/9 (33.3) Not applicable
Positive in DIFe 6/24 (25.0) 2/11 (18.2) 0/3 (00.0) 0/0 0/0 2/5 (40.0) 3/3 (100.0) 2/5 (40.0)
DIFþ ¼ direct immunofluorescent positive; DIFe ¼ direct immunofluorescent negative.
*Nonocular, nasopharyngeal, genital, and skin categories are not mutually exclusive.
yNumbers and percentages are for white races: mucous membrane pemphigoid patients additionally included 2 Asian persons, 1 Black person, and 3 persons of other races; control participants additionally
included 2 Asian persons and 1 Black person.
zMissing values for race and direct immunofluorescent results are shown. These were excluded from the denominators for calculation of percentages.
xDirect immunofluorescent-negative patients all showed ocular involvement: 11 of 24 (45.8%) showed ocular-only involvement, 3 of 24 (12.5%) showed ocular and oral involvement only, and the


















Figure 1. Bar graph comparing serum pemphigoid autoantibody detection test results for all mucous membrane pemphigoid (MMP) patients (n ¼ 76) with
those of all control participants (n ¼ 45). Individual tests are numbered 1 through 5, and test combinations are referred to by these numbers. The numbers
from which the percentages are derived are given in Table 1. Youden’s index is shown only when a significant (or borderline) difference exists in the
percentage of positive reactions. P values of 0.05 or less are highlighted in red. ELISA ¼ enzyme-linked immunosorbent assay; IgA ¼ immunoglobulin
A; IgG ¼ immunoglobulin G; IIF ¼ indirect immunofluorescence; Sn ¼ sensitivity; Sp ¼ specificity; SSS ¼ salt-split skin.
Dart et al  Serum Autoantibody Tests for Ocular Pemphigoidreactions in MMP patients compared with control participants.
Youden’s index (sensitivity% þ specificity% e 100) was used to
identify the best diagnostic test, giving equal weight to specificity
and sensitivity and taking the clinical diagnosis of MMP as the
reference standard. Youden’s index of 100% indicates a perfect
diagnostic test and more than 80% is an acceptable value for a
good test. The above procedures were repeated for some combi-
nations of different tests, whereby the serologic results were
regarded as positive when 1 or more tests of the combination
showed a positive reaction. The aim was to explore combinations
that improved sensitivity or specificity or gave a higher Youden’s
index. The frequency of positive reactions in control participants
and in both DIFþ and DIFe MMP patients were also compared
using the Fisher exact test. The frequency of positive reactions in
control participants and MMP clinical phenotypes (MMP involving
different combinations of sites) were compared using the Fisher
exact test, as appropriate.Results
Characteristics of Mucous Membrane
Pemphigoid Patients and Control Participants
Table 1 describes the serologic tests and the results of both
individual tests and test combinations for all patients combined
compared with control participants. Table S1 (available at
www.aaojournal.org) provides full clinical and serologic data forthe individual patients and control participants. This dataset is
also available as an Excel Workbook (Microsoft, Redmond, WA)
at Mendeley Data (https://data.mendeley.com/datasets/
7pxbkx84r3/1) including the patient and control dataset in sheet
1 and serologic results from all 3 laboratories in sheet 2. Table 2
summarizes the demographic data and overall positive serologic
test results for patients with different sites of MMP involvement
and by DIF status. Mucous membrane pemphigoid patients and
control participants were similar in terms of age, gender, and
race distribution.
Direct Immunofluorescence
A DIF result was available for 73 of 76 MMP patients. Direct
immunofluorescence showed positive results for at least 1 site in
49 of 73 patients (67.1%). We included the 24 patients with
negative DIF results and the 3 for whom these results were not
available but who met our clinical criteria for a diagnosis of
MMP.3 All 24 DIFe patients showed ocular involvement
(Table 2).
Serum Pemphigoid Autoantibody Tests
When all tests were evaluated for patients and control participants,
at least 1 positive test result was reported for 29 of 76 MMP pa-
tients (38.2%); 22 of 49 (44.9%) direct IIF-positive patients
showed positive results versus 6 of 24 (25%) DIFe patients
(Table 2).5
Figure 2. Bar graph comparing serum pemphigoid autoantibody detection test results from direct immunofluorescence-positive (DIFþ) patients (n ¼ 49)
and direct immunofluorescence-negative (DIFe) patients (n ¼ 24). Individual tests are numbered 1 through 5: (1) enzyme-linked immunosorbent assay
(ELISA) BP180-NC16a MBL, (2) ELISA BP230 MBL, (3) immunoglobulin A (IgA) indirect immunofluorescence (IIF) salt-split skin (SSS), (4)
immunoglobulin G (IgG) IIF SSS, and (5) keratinocyte footprint assay (KFA). Tests 3 and 5 were not analyzed for differences between DIFþ and DIFe
patients because of small numbers. Percentages are given here for which the numbers are provided in Table S2. P values of 0.05 or less are highlighted in red.
cf ¼ compared with.
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Patients and Control Participants with Positive
Serum Pemphigoid Autoantibody Results for
Individual Tests and Test Combinations
For individual tests results for the entire patient group (Table 1),
only ELISA BP180-NC16a MBL and IgG IIF SSS results were
significantly different from those of control participants. Control
sera showed positive results in 2 tests: 2 of 45 samples (4.44%) for
the ELISA BP180-NC16a MBL and 1 of 45 samples for the ELISA
BP230 MBL. These findings are shown graphically in Figure 1.
Test combinations (any 1 or more positive test results) showed
substantially higher sensitivities than any individual test, with
similar specificities, although sensitivities were still low (17.1%e
38.2%), contributing to a low Youden’s index. The ELISA
BP180-NC16a MBL, IIF on SSS for IgG and IgA, and laminin
332 assay were an optimal combination, with a sensitivity of 36.8
and specificity of 95.56. When all 5 tests were combined, the
sensitivity rose slightly to 38.16 but with a slightly reduced spec-
ificity of 93.33 because 1 control sample showed positive results
for BP230.
Table S2 (available at www.aaojournal.org) is expanded from
Table 1 to include the serologic test results for the following6
additional patient subsets compared with control participants:
DIFþ and DIFe patients, the sites most frequently involved
by MMP (ocular only, oral only, ocular and oral only, and all
nonocular sites), and results for DIFþ nonocular patients. The
latter group was chosen because of our unanticipated finding
showing that ocular-only patients and DIFe ocular patients
with multisite involvement included a lower proportion of pa-
tients with detectable pemphigoid autoantibodies. These results
are illustrated in Figure 2, showing the test reactivity for the
comparison of DIFe and DIFþ patients compared with
control participants, and in Figure 3, showing the test
reactivity for the following different MMP phenotypes: ocular
only, oral only, ocular and oral only, and all nonocular sites
of involvement.
Proportions of Patients with Positive Serologic
Results with and without Active Inflammation,
Systemic Immunosuppression, or Both
Table S3 (available at www.aaojournal.org), for patients with oral
or ocular MMP or both (n ¼ 74), shows a strong association with
disease activity but not with immunosuppression, probably because
32 of 43 immunosuppressed patients (74.4%) still had active
inflammation.
Figure 3. Bar graph comparing serum pemphigoid autoantibody detection test results from mucous membrane pemphigoid (MMP) phenotypes defined by
MMP site involvement with those from control participants. Individual tests are numbered 1 through 5: (1) enzyme-linked immunosorbent assay (ELISA)
BP180-NC16a MBL, (2) ELISA BP230 MBL, (3) immunoglobulin A (IgA) indirect immunofluorescence (IIF) salt-split skin (SSS), (4) immunoglobulin G
(IgG) IIF SSS, and (5) keratinocyte footprint assay (KFA). P values of 0.05 or less (exact 2-sided) are shown at end of bars, each compared with controls.
Percentages are used here for which the numbers are provided in Table S2.
Dart et al  Serum Autoantibody Tests for Ocular PemphigoidProportions of Direct Immunofluorescence-
Positive and -Negative Patients with Positive
Serum Basement Membrane Autoantibody
Reactivity for Individual and Test Combinations
Figure 2 and Table S2 show that, with 3 exceptions, DIFþ
patients showed significantly different (more often positive)
serologic findings both for single tests and all test combinations
compared with control participants. Patients with negative DIF
results with positive BP230 ELISA results, BP180-NC16a/IIF
SSS combination results, or combinations of ELISAs, IIF SSS,
and laminin 332 assay results were significantly different from
control participants (Fig 2), although the sensitivity is low for
these tests (Fig 1).
Proportions of Patients with Ocular-Only, Oral-
Only, Ocular- and Oral-Only, and All Nonocular
Sites Involved by Mucous Membrane
Pemphigoid with Positive Serum Basement
Membrane Autoantibody Reactivity for
Individual Tests and Test Combinations
In ocular-only patients, only 1 of 6 DIFþ patients showed pos-
itive serum test results, as opposed to 12 of 19 DIFþ nonocular
patients (Table 2), suggesting that there may be lower levels of
detectable autoantibodies in ocular disease patients independentof DIF status. Figure 3 and Table S2 show that for ocular-only
MMP sites of involvement, no significant difference was found
in test reactivity compared with control participants for both
individual tests and any test combinations. This finding was
similar but less extreme for patients with both ocular- and oral-
only involvement (n ¼ 15) for whom no individual test results
were significant. For all DIFe patients (n ¼ 24), positive BP230
ELISA (4/24) results were significantly different, as were test
combinations including at least 1 positive ELISA result, 1 pos-
itive IIF SSS (6/24) result, or both in patients compared with
control participants. Conversely for pure oral involvement and
any patients with nonocular site involvement (all but one of
whom was DIFþ), test reactivity was significantly different from
control participants for both ELISAs and IgG SSS, as well as all
test combinations.Discussion
This cross-sectional study of 76 patients with a clinical
diagnosis of MMP included 24 (32.9%) who were DIFe but
who met clinical and pathologic criteria for DIFe MMP
with ocular involvement3,8,18,22,23 and included 18 patients
with ocular-only MMP (6/18 DIFþ). To our knowledge,
this is the largest study of ocular-only MMP studied to
date.2,15 Serum pemphigoid autoantibodies were detected in7
Figure 4. Guideline showing a test strategy for the diagnosis of MMP with ocular involvement in subjects with cicatrising conjunctivitis. ELISA ¼ enzyme
linked immunosorbent assay; IgA ¼ immunoglobulin A; IgG ¼ immunoglobulin G; MMP ¼ mucous membrane pemphigoid.
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Dart et al  Serum Autoantibody Tests for Ocular Pemphigoid29 of 76 MMP patients (38.2%) compared with 3 of 45
control participants (6.7%) in whom positive results were
found only for ELISAs. The proportions of autoantibodies
detected in DIFþ MMP patients was higher at 22 of 49
patients (44.9%) compared with DIFe MMP at 6 of 24
patients (25%). Laminin 332 assay results were positive in
3 DIFþ MMP patients. Serologic results were more often
positive in patients with active inflammation.
Our primary hypothesis was that a panel of serum pem-
phigoid autoantibody tests might be used to confirm an
immunopathologic diagnosis of MMP in DIFe patients with
ocular MMP involvement. All DIFe patients showed ocular
involvement. For DIFe patients, the only serologic test that
was significantly different in patients compared with control
participants was that for BP230 reactivity (positive in 4 of 24
patients). However, a test combination including at least 1
positive ELISA result and 1 positive IIF SSS result increased
the proportion of positive test results (6/24 tests) and was
significantly different from control participants (Table S2; Fig
2) but with low sensitivity (approximately 30%). For ocular-
only MMP (n ¼ 18), only 3 of 90 tests showed positive re-
sults, not significantly different from that for control partici-
pants. In summary, we found only limited support for our
primary hypothesis by finding that this panel of widely
available serologic tests do not contribute to the immuno-
pathologic diagnosis of ocular-only MMP, although they are
of limited value in DIFe MMP multisite ocular disease. It is
unsurprising that patients who do not have antibodies at the
epithelial BM (DIFe) that are probably deposited from the
circulation are also less likely to have detectable circulating
antibodies. Our findings for ocular-only MMP confirm those
of 2 other studies of a total of 16 patients.2,15
One potential shortcoming of this study may result from
antibody degradation resulting from the storage methodol-
ogy and the time between sample collection and analysis.
We think this unlikely because antibody function in serum
stored at e20 C to e80 C is recommended for up to 10
years24 and has been shown to be stable for this period25 and
because our ELISAs more often showed positive results
when duplicate sera were retested in Groningen and St.
John’s 4 to 5 years after initial testing at the service
laboratory. Another shortcoming may relate to
misclassification of our ocular-only MMP patients. We
believe this unlikely given that the strict criteria we have
used recently became well established and coupled with the
recognition that DIF and serologic findings may be negative
in ocular MMP.3,8,18,22,23 Our serologic results are
compared with those of 13 similar MMP
autoantibody studies in Table S4A (available at
www.aaojournal.org)2,13,16,26e35 and with 3 studies of
control populations in Table S4B.19,36,37 Our findings for
BP180 and BP230 ELISAs, laminin 332, and IgA IIF SSS
are comparable, whereas our proportions of participants
showing positive IgG IIF SSS results are among the
lowest reported. Differences in the proportions of routine
tests that show positive results relate both to differences in
disease activity and in serum reactivity for MMP
involving different anatomic sites, as we have shown in
this study, with both quiescent disease and ocular sites
having lower reactivity.Strengths of this study are that it is a prospective
hypothesis-driven cross-sectional study for which partici-
pants were diagnosed and phenotyped using previously
agreed-on criteria and that used serologic tests available in
most dermatology immunopathology laboratories. Our re-
sults were duplicated in 2 independent laboratories, and
discrepancies were verified in a third. Our finding of 51 of
468 discrepancies (10.9%) for duplicate testing, of which
only 6 from 1 laboratory could be confirmed, shows that
interpretation of results requires confidence in the quality
standards of the laboratory being used. The study is also
unique (Table S4, available at www.aaojournal.org) in
including, at the time of blood sampling, disease activity
scores, immunosuppression data, a control population, and
serum storage data.
The findings from this study on the value of circulating
autoantibody tests for the immunopathologic diagnosis of
MMP concur with those of previous studies on the poor
sensitivity of DIF in MMP with ocular involvement and the
need for an alternative diagnostic strategy for ocular disease.
Given the low sensitivity of serologic tests in MMP and the
false-positive rate in control participants, the finding of
positive results must be interpreted with caution before us-
ing these as confirmation of a diagnosis of MMP. Our
recommendation for a diagnostic guideline for potential
cases of MMP with ocular involvement arising from these
studies is in Figure 4. Our studies also have implications for
the development of diagnostic tests and the pathogenesis of
MMP. Either current immunopathologic tests are too
insensitive for the detection of low levels of tissue-fixed
or circulating antibodies or a subset of MMP patients ex-
ists in whom an alternative, possibly cell-mediated, immu-
nopathologic reaction directed at the epithelial BM epitopes
is predominant.8 Novel tests for MMP are required that may
include cellular, cytokine, or gene expression biomarkers for
MMP.
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